Submissions for variant NM_000059.4(BRCA2):c.3170_3174del (p.Lys1057fs)

dbSNP: rs80359373

Total submissions: 27

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000031407	SCV000300594	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2016-09-08	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000044141	SCV000072154	pathogenic	Hereditary breast ovarian cancer syndrome	2025-02-03	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Lys1057Thrfs*8) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs781096360, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with breast, ovarian, and pancreatic cancer (PMID: 15131399, 15382066, 16539696, 20694749, 23621881, 25863477, 25864590, 26296701, 27433846). This variant is also known as 3398delAAAAG and 3398del5. ClinVar contains an entry for this variant (Variation ID: 37826). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics	RCV000131091	SCV000186021	pathogenic	Hereditary cancer-predisposing syndrome	2022-04-13	criteria provided, single submitter	clinical testing	The c.3170_3174delAGAAA pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of 5 nucleotides between positions 3170 and 3174, causing a translational frameshift with a predicted alternate stop codon (p.K1057Tfs*8). This alteration is a known French Canadian founder mutation (Oros KK et al. BMC Med. Genet. 2006 Mar;7:23; Janavicius R. EPMA J. 2010 Sep;1:397-412) but has also been reported in multiple breast and/or ovarian cancer cohorts from various ethnicities (Lubinski J et al. Fam. Cancer. 2004;3:1-10; Ghadirian P et al. Clin. Genet. 2009 Nov;76:421-6; Kang E et al. Breast Cancer Res. Treat. 2015 May;151:157-68; Labidi-Galy SI et al. Clin. Cancer Res. 2018 01;24(2):326-333). This alteration was also identified in 1/692 men with metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis (Pritchard CC et al. N. Engl. J. Med. 2016 Aug;375:443-53) and in a 47-year-old man diagnosed with pancreatic ductal adenocarcinoma (Andrei AZ et al. Cancer Lett. 2015 Aug;364:8-16). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
GeneDx	RCV000220190	SCV000278845	pathogenic	not provided	2021-04-22	criteria provided, single submitter	clinical testing	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with hereditary breast and ovarian cancer and is considered a French Canadian pathogenic founder variant (Lubinski 2004, Oros 2006, Janavicius 2010, de Juan Jimenez 2013, Andrei 2015, Belanger 2015, Pritchard 2016); Not observed at a significant frequency in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 3398del5; This variant is associated with the following publications: (PMID: 26296701, 25884701, 23199084, 25863477, 20694749, 28127413, 23479189, 25864590, 26941049, 27433846, 15382066, 16539696, 23621881, 15728167, 15131399, 29084914, 28724667, 30720243, 31447099)
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000220190	SCV000296698	pathogenic	not provided	2023-12-06	criteria provided, single submitter	clinical testing	The BRCA2 c.3170_3174del (p.Lys1057Thrfs*8) variant (also known as 3398del5, 3167_3171del) alters the translational reading frame of the BRCA2 mRNA and causes the premature termination of BRCA2 protein synthesis. In the published literature, this variant has been reported in individuals with breast and/or ovarian cancer (PMIDs: 32885271 (2021), 28724667 (2017), 26296701 (2015), 15728167 (2005)), endometrial cancer (PMID: 29084914 (2018)), pancreatic cancer (PMID: 25864590 (2015)), and prostate cancer (PMID: 27433846 (2016)). This variant has also been described as a founder variant in the French Canadian population (PMID: 23199084 (2010)). The frequency of this variant in the general population, 0.000027 (3/112272 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000031407	SCV000326827	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2015-10-02	criteria provided, single submitter	clinical testing
Counsyl	RCV000031407	SCV000489135	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2016-08-23	criteria provided, single submitter	clinical testing
Cancer Genetics and Genomics Laboratory, British Columbia Cancer Agency	RCV000044141	SCV000586939	pathogenic	Hereditary breast ovarian cancer syndrome	2017-04-18	criteria provided, single submitter	clinical testing
Department of Pathology and Molecular Medicine, Queen's University	RCV000044141	SCV000588089	pathogenic	Hereditary breast ovarian cancer syndrome	2017-04-20	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV000131091	SCV000683533	pathogenic	Hereditary cancer-predisposing syndrome	2024-08-19	criteria provided, single submitter	clinical testing	This variant deletes 5 nucleotides in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is also known as 3398del5 or 3398delAAAAG in the literature. This variant is expected to result in an absent or non-functional protein product. This variant has been identified in more than 15 individuals affected with breast or ovarian cancer (PMID: 16539696, 23479189, 23621881, 25863477, 26296701, 29084914, 33471991), in individuals affected with pancreatic cancer (PMID: 35547873) and in an individual affected with prostate cancer (PMID: 27433846). This variant has been identified in 3/246888 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine	RCV000031407	SCV000839918	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2017-05-25	criteria provided, single submitter	clinical testing	The c.3170_3174del (p.Lys1057Thrfs*8) variant in the BRCA2 gene has been detected in one family from a cohort of cancer patients [PMID 15131399, reported as 3398delAAAAG] and a cohort of patients with prostate cancer [PMID 27433846]. The variant was also reported in 11 patients in the Breast Cancer Information Core database. This 5 bp deletion in exon 11 results in a frameshift and the creation of a premature stop codon. This variant is thus predicted to result in a loss of function of the protein. This variant has been detected in three individuals in the ExAC database (http://exac.broadinstitute.org/variant/13-32911658-CAAAAG-C). This variant thus classified as pathogenic.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV000735538	SCV000901105	pathogenic	Breast and/or ovarian cancer	2023-06-09	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000044141	SCV000918996	pathogenic	Hereditary breast ovarian cancer syndrome	2022-05-04	criteria provided, single submitter	clinical testing	Variant summary: BRCA2 c.3170_3174delAGAAA (p.Lys1057ThrfsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.2e-05 in 246888 control chromosomes. c.3170_3174delAGAAA has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer (eg. Lubinski_2004, Oros_2004, de Juan Jimenez_2013, Ghadirian_2013). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. 14 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV000220190	SCV002048290	pathogenic	not provided	2024-09-24	criteria provided, single submitter	clinical testing	The BRCA2 c.3170_3174delAGAAA; p.Lys1057ThrfsTer8 variant (rs80359373), also known as 3398del5 in traditional nomenclature, has been reported in several individuals affected with breast or ovarian cancer (Ellingson 2015, Labidi-Galy 2018, Lubinski 2004, Kang 2015, Sun 2017). The variant is reported as pathogenic by several sources in the ClinVar database (Variation ID: 37826) and is reported in the general population with an overall allele frequency of 0.001% (3/246888 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting five nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Ellingson MS et al. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep;153(2):435-43. Labidi-Galy SI et al. Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. Clin Cancer Res. 2018 Jan 15;24(2):326-333. Lubinski J et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3(1):1-10. Kang E et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015 May;151(1):157-68. Sun J et al. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res. 2017 Oct 15;23(20):6113-6119.
Revvity Omics, Revvity	RCV000220190	SCV003816168	pathogenic	not provided	2022-11-30	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV003460505	SCV004213625	pathogenic	Familial cancer of breast	2024-02-10	criteria provided, single submitter	clinical testing
All of Us Research Program, National Institutes of Health	RCV004803014	SCV004845116	pathogenic	BRCA2-related cancer predisposition	2024-02-28	criteria provided, single submitter	clinical testing	This variant deletes 5 nucleotides in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is also known as 3398del5 or 3398delAAAAG in the literature. This variant is expected to result in an absent or non-functional protein product. This variant has been identified in more than 15 individuals affected with breast or ovarian cancer (PMID: 16539696, 23479189, 23621881, 25863477, 26296701, 29084914, 33471991), in individuals affected with pancreatic cancer (PMID: 35547873) and in an individual affected with prostate cancer (PMID: 27433846). This variant has been identified in 3/246888 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000044141	SCV004848525	pathogenic	Hereditary breast ovarian cancer syndrome	2021-07-15	criteria provided, single submitter	clinical testing	The p.Lys1057ThrfsX8 variant in BRCA2 is considered to be a founder variant in the French Canadian individuals with BRCA2-associated cancers (Oros 2006 PMID:16539696, Cavallone 2010 PMID:20694749, Ghadirian 2014 23621881) and has also been reported in affected individuals from other populations (Kang 2015 PMID:25863477, Sun 2017 PMID:28724667). This variant was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1057 and leads to a premature termination codon 8 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the BRCA2 gene is an established disease mechanism for hereditary breast and ovarian cancer (HBOC). Additionally, this variant was classified as pathogenic on Sep 08, 2016 by the ClinGen-approved ENIGMA expert panel (Variation ID 37826). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP criteria applied: PVS1, PS4, PM2_supporting.
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital	RCV000220190	SCV005090024	pathogenic	not provided	2025-03-04	criteria provided, single submitter	clinical testing
Clinical Genetics Laboratory, Skane University Hospital Lund	RCV000220190	SCV005199048	pathogenic	not provided	2023-05-08	criteria provided, single submitter	clinical testing
Sharing Clinical Reports Project (SCRP)	RCV000031407	SCV000054012	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2013-01-31	no assertion criteria provided	clinical testing
Breast Cancer Information Core (BIC) (BRCA2)	RCV000031407	SCV000146184	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2004-02-20	no assertion criteria provided	clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto	RCV000044141	SCV000587662	pathogenic	Hereditary breast ovarian cancer syndrome	2014-01-31	no assertion criteria provided	research
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001353919	SCV000591849	pathogenic	Malignant tumor of breast		no assertion criteria provided	clinical testing	The BRCA2 p.Lys1057ThrfsX8 variant was identified in 26 of 11800 proband chromosomes (frequency: 0.002) from individuals or families with breast, ovarian, and metastatic prostate cancer (Lubinski 2004 PMID:15131399, Oros 2006 PMID:16539696, Oros 2004 PMID:15382066, Ghadirian 2009 PMID:19863560, Claus 2005 PMID:15728167, Pritchard 2016 PMID:27433846, Kang 2015 PMID:25863477, Belanger 2015 PMID:25884701). The variant was also identified in the following databases: dbSNP (ID: rs781096360) as “With Pathogenic allele”, ClinVar (14x as pathogenic by ENIGMA, CIMBA, Counsyl, COGR, Invitae, Ambry, GeneDx, Quest Diagnostics, Color Genomics, SCRP, BIC), Clinvitae (4x as pathogenic by ClinVar, Invitae), LOVD 3.0 (1x, with a pathogenicity prediction as "affects function"), UMD-LSDB (5 x as a causal variant), BIC Database (11x with clinical importance) and ARUP Laboratories (1x, as "5-definitely pathogenic"). The variant was not identified in Cosmic, MutDB and Zhejiang Colon Cancer Databases. The variant was also identified by our laboratory in 8 individuals with breast or ovarian cancer. The p.Lys1057ThrfsX8 variant is described in the literature as a recurrent mutation in French Canadian cohorts, with haplotype analyses suggesting that this may be a founder mutation in this population (Oros 2004 PMID:15382066, Oros 2006 PMID:16539696, Ghadirian 2009 PMID:19863560, Janavicius 2010 PMID:23199084, Belanger 2015 PMID:25884701). The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.3170_3174del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 1057 and leads to a premature stop codon, 8 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in BRCA2 related cancers and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research	RCV000735538	SCV000863676	pathogenic	Breast and/or ovarian cancer	2015-10-02	no assertion criteria provided	clinical testing
BRCAlab, Lund University	RCV000031407	SCV002588862	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2022-08-26	no assertion criteria provided	clinical testing
PreventionGenetics, part of Exact Sciences	RCV004732561	SCV005347798	pathogenic	BRCA2-related disorder	2024-07-03	no assertion criteria provided	clinical testing	The BRCA2 c.3170_3174del5 variant is predicted to result in a frameshift and premature protein termination (p.Lys1057Thrfs*8). This variant (aka 3398delAAAAG) is a recurrent variant among French Canadians (Oros et al. 2006. PubMed ID: 16539696) and has been reported in patients with a range of different cancers including breast, ovarian, prostate, and pancreatic cancers (Lubinski et al. 2004. PubMed ID: 15131399; Labidi-Galy et al. 2018. PubMed ID: 29084914; Andrei et al. 2015. PubMed ID: 25864590; Kang et al. 2015. PubMed ID: 25863477; Ellingson et al. 2015. PubMed ID: 26296701; Pritchard et al. 2016. PubMed ID: 27433846). This variant is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/37826/). This variant is reported in 0.0027% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in BRCA2 are expected to be pathogenic. This variant is interpreted as pathogenic.